In this podcast episode, we explore how the FDA’s new emphasis on overall survival (OS) as the gold standard for oncology drug approvals is reshaping cancer research and development. This shift raises the evidentiary bar for demonstrating true clinical benefit, requiring more rigorous and longer trials, but also creating opportunities for AI to transform the process. From preclinical drug design to survival outcome modeling, AI enables better candidate selection, deeper biological insights, and virtual trial simulations that predict long-term patient outcomes. By integrating safety, efficacy, and survival projections, AI-native drug discovery programs can deliver therapies that not only shrink tumors but also extend lives. Produced by Dr. Jake Chen.